Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2010

View Archived Issues

Basilea Pharmaceutica claims new antibacterial agents

Avexa and Shanghai TargetDrug describe new NS5B inhibitors

Orchid Chemicals & Pharmaceuticals discovers new PDE4 inhibitors

Hybrigenics presents new USP7 inhibitors

German scientists disclose new antiarrhythmic agents

Algeta begins phase I/IIa trial of Alpharadin/docetaxel combination in CRPC

Herceptin approved in Canada for HER2-positive stomach cancer

Epitherix identifies novel chemical scaffolds targeting Wnt pathway

Karo Bio to present phase III development plan for eprotirome in high-risk HeFH

Carbamazepine enhances autophagy and decreases hepatic fibrosis in vivo

Serum uric acid level is a biomarker for new-onset diabetes

Scientists select new H3 receptor antagonists as clinical candidates for sleep disorders

Scientists identify potential susceptibility loci for endometriosis

Midbrain [18F]-fallypride PET can reveal impulsivity in individuals

Dr. Reddy's launches biosimilar darbepoetin alfa for anemia in India

Crucell, IAVI and BIDMC to conduct phase I AdVac-based AIDS vaccine trial

D-Pharm reports results from DP-b99 cardiac safety study

FDA approves NovoSeven RT 8-mg vial for hemophilia A and B

FDA clears Curemark's IND for CM-4612 in ADHD

Healthpoint advances Collagenase Santyl for diabetes-associated foot ulcers

Pathway Therapeutics raises funds for PI3K inhibitor development

Trigemina reports phase IIa data on TI-001 in chronic daily headache

ACT and Brown Cancer Center collaborate to identify cancer therapeutics

Biotest reports final data from phase IIa trial of BT-061 in RA

Biotest updates development program for BT-062 in multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...